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The small noncoding 
RNAs (sncRNAs) of murine 
gammaherpesvirus 68 (MHV-68) are 
involved in regulating the latent-to-
lytic switch in vivo
Beatrix Steer1, Martin Strehle1, Christine Sattler1,2, Dagmar Bund1, Britta Flach1, 
Tobias Stoeger2, Jürgen G. Haas3 & Heiko Adler1
The human gammaherpesviruses Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus 
(KSHV), which are associated with a variety of diseases including tumors, produce various small 
noncoding RNAs (sncRNAs) such as microRNAs (miRNAs). Like all herpesviruses, they show two 
stages in their life cycle: lytic replication and latency. During latency, hardly any viral proteins are 
expressed to avoid recognition by the immune system. Thus, sncRNAs might be exploited since they 
are less likely to be recognized. Specifically, it has been proposed that sncRNAs might contribute 
to the maintenance of latency. This has already been shown in vitro, but the respective evidence in 
vivo is very limited. A natural model system to explore this question in vivo is infection of mice with 
murine gammaherpesvirus 68 (MHV-68). We used this model to analyze a MHV-68 mutant lacking the 
expression of all miRNAs. In the absence of the miRNAs, we observed a higher viral genomic load during 
late latency in the spleens of mice. We propose that this is due to a disturbed regulation of the latent-to-
lytic switch, altering the balance between latent and lytic infection. Hence, we provide for the first time 
evidence that gammaherpesvirus sncRNAs contribute to the maintenance of latency in vivo.
Long and small noncoding RNAs (ncRNAs) including microRNAs (miRNAs) produced by eukaryotic cells con-
tribute to a variety of cellular processes like gene expression and genome maintenance1. Similar to their host cells, 
many viruses also produce ncRNAs. Among the viruses, herpesviruses produce most ncRNAs which might be 
related to their large genomes and their particular life cycle2, consisting of a lytic and a latent phase. In the lytic 
phase, all viral gene products are expressed and infectious progeny is produced while in the latent phase, the 
double-stranded DNA genome is maintained in the host cell but only a few viral gene products are expressed2. 
Therefore, during latency, the use of ncRNAs like miRNAs instead of viral proteins for the regulation of viral 
persistence might be of advantage for the virus as ncRNAs are less likely to be recognized by the host immune 
system2.
Great efforts have been made to unravel the targets and the functions of viral ncRNAs, particularly of 
virus-encoded miRNAs. The latter are approximately 22 nucleotide-long ncRNAs, which are generated from 
stem-loop precursors. Mature miRNAs directly interact with a member of the Argonaute protein family to form 
the RNA-induced-silencing-complex (RISC), which silences gene expression post-transcriptionally by binding 
to the 3′ untranslated regions of target mRNAs (reviewed, for example, in3–5). During the past years, so-called rib-
onomics approaches for miRNA target analysis, for example RIP-Chip (RNA immunoprecipitation coupled with 
1Comprehensive Pneumology Center, Research Unit Lung Repair and Regeneration, Helmholtz Zentrum München - 
German Research Center for Environmental Health (GmbH), Member of the German Center of Lung Research (DZL), 
Marchioninistrasse 25, D-81377 Munich, Germany. 2Institute of Lung Biology and Disease, Comprehensive Pneumology 
Center, Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Member of the 
German Center of Lung Research (DZL), Ingolstädter Landstrasse 1, D-85764 Neuherberg, Germany. 3Division 
of Infection and Pathway Medicine, University of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SB, UK. 
Correspondence and requests for materials should be addressed to H.A. (email: h.adler@helmholtz-muenchen.de)
Received: 12 May 2016
Accepted: 02 August 2016
Published: 26 August 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:32128 | DOI: 10.1038/srep32128
microarray analyses), CLIP (crosslinking and immunoprecipitation), HITS-CLIP (high-throughput sequenc-
ing of crosslinked RNA fragments) and PAR-CLIP (photoactivatable-ribonucleotide-enhanced crosslinking)6  
have been applied and led to the identification of numerous herpesviral miRNA targets7–10. Besides the identi-
fication of potential targets of a herpesviral miRNA, the demonstration of its biological function, preferentially 
in the context of viral infection, is needed to finally define its role in infection and pathogenesis11. Using various 
model systems combined with reverse genetics approaches, important roles for herpesviral ncRNAs in the viral 
life cycle and in pathogenesis have been described, including the regulation of viral persistence, host cell pro-
liferation, long-term survival of host cells and immune evasion (reviewed, for example, in11–22). However, the 
biological functions have so far largely been explored in in vitro systems whereas the respective knowledge during 
infection in vivo is still very limited. To understand the biological relevance, in vivo systems are essential23,24. 
In this regard, progress has recently been made for miRNAs encoded by different members of all three her-
pesvirus subfamilies. The human alphaherpesviruses herpes simplex virus (HSV)-1 and HSV-2 are able to also 
infect various animals and can thus be studied in vivo. Mutation of the miRNA hsv1-miR-H2 of HSV-1 led to 
increased encephalitis in mice and to increased reactivation from latency ex vivo25. However, a combined knock-
out of miRNAs hsv1-miR-H2, -H4, -H5 and -H6 did not affect replication and levels of latent virus in infected 
mice26. The miRNA hsv2-miR-H6 of HSV-2 was shown to contribute to pathogenesis in guinea pigs: Disruption 
of hsv2-miR-H6 resulted in attenuation of neurological symptoms while it did not affect replication or levels of 
latent virus27. Pseudorabies virus (PRV) is an alphaherpesvirus of pigs, thus, experimental infection of pigs repre-
sents a robust natural model to investigate the in vivo function of miRNAs. Deletion of 9 of the 11 PRV miRNAs 
did neither affect replication nor latency establishment in infected pigs28. Marek’s disease virus-1 (MDV-1) is an 
avian alphaherpesvirus, hence, as with PRV infection of pigs, infection of chickens represents a very good natural 
model to investigate the in vivo function of miRNAs. Using this model, Zhao et al. demonstrated a critical role for 
mdv1-miR-M4, a functional ortholog of the cellular oncomir miR-155, in MDV-1 induced lymphomagenesis29, 
and Teng et al. demonstrated that additional MDV-1 encoded miRNAs also contribute to tumorigenesis30. For the 
human betaherpesvirus human cytomegalovirus (HCMV) which encodes 17 mature miRNAs, infection of mice 
with murine cytomegalovirus (MCMV) offers a model to study the in vivo function of viral miRNAs in a natural 
host23. Mutation of two (mcmv-miR-M23-2 and mcmv-miR-m21-1) out of the 29 mature miRNAs encoded by 
MCMV resulted in reduced salivary gland replication in C57BL/6 mice due to compromised immune evasion31. 
The human gammaherpesviruses Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV) 
encode for 44 and 25 mature miRNAs, respectively23. In vivo investigation of their role is difficult due to the strict 
species specificity of both viruses. Nevertheless, by using humanized mice, insights into in vivo functions of EBV 
and KSHV miRNAs could be obtained. For example, an EBV mutant with a deletion of the three BHRF-1 miR-
NAs displayed a delay in systemic viral DNA accumulation in humanized mice but did not affect virus-induced 
oncogenesis32. Xenotransplantation of EBV-negative cells ectopically expressing EBV miR-BART7-3p increased 
the development of metastases33, and ectopic expression of all BART miRNAs potentiated tumor growth in a 
mouse xenograft model34. Similarly, transplantation of human hematopoietic progenitors stably expressing 
KSHV miR-K12-11, an ortholog of the cellular miR-15535,36, into immunodeficient mice resulted in a strong 
B-cell expansion37,38.
A natural model system to investigate gammaherpesvirus-host interaction including the in vivo function of 
gammaherpesvirus miRNAs is the infection of mice with murine gammaherpesvirus 68 (MHV-68), a natural 
pathogen of wild rodents39. MHV-68 encodes for 14 pre-miRNA stem-loops giving rise to 28 mature miRNAs40–42. 
The stem-loop sequences are incorporated into 8 viral tRNA (vtRNA) sequences which are under the regulation 
of RNA-Polymerase III. It has been shown that the generation of the MHV-68 miRNAs is dependent on the A/B 
boxes in these vtRNA sequences and on the presence of tRNase Z and Dicer, but not on Drosha43,44. Uncovering 
the function of these vtRNA-miRNA-encoding sequences has only just started. Feldman et al.45 and Diebel 
et al.46 demonstrated that after intranasal inoculation of C57BL/6 wildtype mice, mutants lacking the expression 
of all miRNAs undergo normal acute lytic replication in lungs but show a subtle latency phenotype, reflected by a 
slightly reduced latency load at early latency (around two weeks after infection). Notably, the mutants displayed a 
striking attenuation of lethal pneumonia in Balb/c IFN-γ−/− mice.
Here, we analyze an independently generated MHV-68 mutant lacking the expression of all miRNAs in sev-
eral animal models including C57BL/6 wildtype mice and IFN-γ-R−/− mice. First, we test whether our mutant 
would display a phenotype consistent with the previous findings of Feldman et al.45 and Diebel et al.46. This was 
crucial since the mutants have been generated in different ways. Second and most importantly, we extend the pre-
vious studies to the phase of late latency (around six weeks after infection). We show that during late latency, the 
absence of the sncRNAs results in a higher viral genomic load in the spleen. Hence, we provide for the first time 
evidence that gammaherpesvirus sncRNAs contribute to the maintenance of latency in vivo.
Results
Generation of MHV68 vtRNA/miRNA knockout viruses. As explained above, the vtRNAs and miR-
NAs of MHV-68 are very tightly linked. As described in the following, we do not differentiate between the vtRNAs 
and miRNAs, and therefore refer to the vtRNA-miRNA-encoding sequences as “sncRNAs” in our manuscript. 
To investigate the function of the sncRNAs of MHV-68, we constructed a mutant lacking all known sncRNAs 
(designated as sncRNA ko) using MHV-68 cloned as bacterial artificial chromosome (BAC)47. To exclude the 
possibility that the observed results were due to rearrangements outside the mutated regions, a revertant of the 
sncRNAs ko mutant (designated as sncRNA ko-revertant) was also generated. The recombinant MHV-68 used in 
this study are schematically depicted in Fig. 1A. All BAC plasmids were characterized by restriction enzyme anal-
ysis (Fig. 1B), Southern blot analysis (Fig. 1C) and by sequencing across the mutated regions which all yielded the 
expected results. To exclude that the genome manipulations affected neighbouring genes, transcription of open 
reading frames M1, M2 and M3 was determined by quantitative RT-PCR 48 hours after infection of NIH3T3 cells 
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with parental virus, sncRNA ko and sncRNA ko-revertant, respectively. No significant differences were observed 
(Supplementary Figure S1). Finally, the expression of all known MHV-68 encoded miRNAs was assessed. For 
this purpose, total RNA was isolated 48 hr after infection of NIH3T3 cells, and the analysis of the expression of 
the MHV-68 miRNAs was performed by LC Sciences (Houston, Texas, USA) using custom miRNA microarrays. 
Similar as in case of cellular miRNAs, some precursor miRNAs (miR-M1-2) only led to the expression of one 
mature miRNA isoform in parental MHV-68 infection. No mature miR-M1-4, miR-M1-10, miR-M1-11 and miR-
M1-12 miRNAs were detected in these cells after lytic infection. As expected, no MHV-68 miRNA expression at 
all was detected after infection with the sncRNA ko while parental virus and sncRNA ko-revertant displayed a 
very similar pattern of miRNA expression (Fig. 2). We conclude from these data that the sncRNA ko and sncRNA 
ko-revertant represent useful tools to investigate the function of the sncRNAs of MHV-68 both in vitro and 
in vivo.
Lytic replication in vitro. To analyze whether deletion of the MHV-68 sncRNAs has any effect on lytic rep-
lication in vitro, NIH3T3 cells were infected with sncRNA ko and parental virus, respectively, and virus titers at 
different time points after infection were determined. No significant differences were observed (Fig. 3), indicating 
that the sncRNAs are not needed for lytic replication in NIH3T3 cells in vitro.
Lytic replication in vivo in C57BL/6 wildtype mice. Intranasal (i.n.) inoculation of mice results in an 
acute phase of lytic virus replication in the lung which mainly involves alveolar epithelial cells39. Thus, to analyze 
whether deletion of the MHV-68 sncRNAs has an effect on lytic replication in vivo, C57BL/6 mice were inocu-
lated i.n. with 5 × 104 PFU of parental virus, sncRNA ko and sncRNA ko-revertant, respectively. Lungs of mice 
were harvested at day 3 (Fig. 4A) and at day 6 (Fig. 4B) after infection, and virus titers were determined from 
organ homogenates by plaque assay. No significant differences were observed, indicating that the sncRNAs are 
dispensable for lytic replication in the lungs of C57BL/6 mice.
Figure 1. Construction and characterization of the sncRNA ko and sncRNA ko-revertant. (A) Scheme 
of the recombinant viruses generated. The boxed red “X” schematically represent the deletions and the black 
triangles (▶) the tRNAs. (B) Structural analysis of BAC plasmids by ethidium bromide-stained agarose gel 
analysis of ApaLI-digested DNA. The lanes show parental BAC (lane 1), sncRNA ko BAC (lane 2) and sncRNA 
ko-revertant BAC (lane 3). Marker (M) sizes (in kilobase pairs) are indicated on the left. (C) Southern blot 
analysis of the gel shown in panel B using a DIG-labeled probe corresponding to nucleotides 9340 to 10104 
(indicated as “P” in panel A). The white dots in panel B and the arrowheads in panel C indicate the expected 
fragments of 10,2 kb, 8,1 kb and 10,5 kb for parental BAC, sncRNA ko BAC and sncRNA ko-revertant BAC, 
respectively.
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Early latency in C57BL/6 wildtype mice. After i.n. inoculation, the spleen is a major site of latently 
infected cells, and the establishment of latency is accompanied by a transient splenomegaly39,48. Thus, spleen 
weight, ex vivo reactivation of latently infected splenocytes and the viral genomic load in the spleen were deter-
mined 17 days after infection (early latency). At this stage, the majority of cells in the spleen harbouring MHV-
68 are B cells39. Spleens were harvested and the spleen weights were taken. Single splenocyte suspensions were 
prepared and analyzed in the ex vivo reactivation assay or used for DNA isolation for real-time PCR analysis. 
After infection with the sncRNA ko, moderately but significantly reduced spleen weights were observed, when 
compared to infection with parental virus or sncRNA ko-revertant (Fig. 5A). Likewise, ex vivo reactivation was 
slightly reduced after infection with the sncRNA ko, with frequencies of reactivation being 1 in 29653, 1 in 70091 
and 1 in 12144 for parental virus, sncRNA ko and sncRNA ko-revertant, respectively (P = 0.086 for parental 
virus versus sncRNA ko, and P = 0.030 for sncRNA ko versus sncRNA ko-revertant; Student’s t-test) (Fig. 5B). 
In contrast, the viral genomic load in the spleen was not reduced after infection with the sncRNA ko (P = 0.026 
Figure 2. miRNA expression analysis. NIH3T3 cells were cultured in 6-well plates and infected with the 
indicated viruses at an MOI of 1, or were left uninfected. For each condition, three biological replicates 
were done. Total RNA was isolated 48 hr p.i., and the analysis of the expression of the MHV-68 miRNAs 
was performed by LC Sciences (Houston, Texas, USA) using custom miRNA microarrays. The heatmap was 
generated using the matrix2png web interface64.
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for parental virus versus sncRNA ko, and P = 0.089 for sncRNA ko versus sncRNA ko-revertant; Mann-Whitney 
Rank Sum Test) (Fig. 5C). We conclude from these data that the sncRNAs of MHV-68 somewhat contribute to 
splenomegaly and ex vivo reactivation but not to the overall genomic load in the spleen at early latency.
Late latency in C57BL/6 wildtype mice. Next, we analyzed the viral genomic load at day 42 post infec-
tion (late latency). Interestingly, mice infected with the sncRNA ko displayed a significantly higher viral genomic 
load when compared to infection with parental virus or sncRNA ko-revertant (P = 0.015 for parental virus versus 
sncRNA ko, and P = 0.009 for sncRNA ko versus sncRNA ko-revertant; Student’s t-test) (Fig. 6). The increase in 
viral genomic load was, however, not accompanied by an increased spleen weight or by increased ex vivo reacti-
vation. In fact, ex vivo reactivation was not observed for any group which is in agreement with the literature: The 
frequency of splenocytes reactivating ex vivo strongly decreases between day 16 and 42 after infection with the 
practical consequence that there is hardly any reactivation detectable in the ex vivo reactivation assay at day 42 
after infection39. These data indicate that the absence of the sncRNAs results in a higher viral genomic load in the 
spleen during late latency. To provide evidence that the sncRNAs are indeed expressed in vivo in latently infected 
mice, we exemplarily analysed the expression of mghv-mir-M1-1 in splenocytes of mice infected with parental 
virus. Consistent with previous data by Feldman et al.45, who analyzed miRNA expression from splenocytes 16 
Figure 3. Lytic virus replication in vitro. NIH3T3 cells were infected with the indicated viruses at an MOI of 
0.1. Cells and cell culture supernatants were harvested at different time points after infection, and virus titers 
were determined by plaque assay on BHK-21 cells. Data shown are the means ± SD from three independent 
experiments.
Figure 4. Lytic replication in the lungs of C57BL/6 mice. Mice were inoculated i.n. with 5 × 104 PFU of the 
indicated viruses. Lungs of mice were harvested at day 3 (A) and at day 6 (B) post infection (p.i.). Virus titers 
were determined from organ homogenates by plaque assay. Each symbol represents an individual mouse, and 
the bars represent the median. The data are compiled from two independent experiments.
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days after infection, we could readily demonstrate expression of mghv-mir-M1-1 both at days 16 and 43 after 
infection (Supplementary Figure S2).
Initial analysis of the immune response in C57BL/6 wildtype mice. To get a first idea whether the 
deletion of the MHV-68 sncRNAs might affect the composition of lymphocyte subpopulations in the spleen 
or the humoral immune response after infection, spleens were harvested at day 17 after infection, and spleno-
cytes were analyzed by FACS analysis (Supplementary Figure S3A). While no differences were observed for 
NK1.1-positive NK cells and for CD4- or CD8-positive T-cells, a significant reduction of CD19-positive B cells 
was oberved after infection with the sncRNA ko, when compared to infection with parental virus or sncRNA 
ko-revertant (P = 0.008 for parental virus versus sncRNA ko and for sncRNA ko versus sncRNA ko-revertant; 
Mann-Whitney Rank Sum Test). In addition, blood was collected at days 17 and 42 after infection, and MHV-68 
specific antibodies in the sera were determined by ELISA (Supplementary Figure S3B). No differences in antibody 
titers between the groups were observed. We conclude from these data that the sncRNAs of MHV-68, consistent 
with the results concerning splenomegaly and ex vivo reactivation, contribute to the expansion of CD19-positive 
B cells at early latency.
Lytic replication in vivo in IFN-γ-R−/− mice. To further substantiate the results obtained in wildtype 
C57BL/6 mice in another model system, and since IFN-γ has been shown to be involved in limiting MHV-68 
reactivation from latency49, we next analyzed the role of the MHV-68 sncRNAs during infection of IFN-γ-R−/− 
mice. IFN-γ-R−/− mice infected with wildtype MHV-68 are not different to wildtype mice when lytic virus titers 
in the lungs are regarded but display a marked loss of splenocytes (resulting in a shrunken spleen) and a greater 
Figure 5. Early latency in the spleen of C57BL/6 mice. Mice were inoculated i.n. with 5 × 104 PFU of the 
indicated viruses. At day 17 after infection, spleens were harvested, and the spleen weights were taken. Single 
splenocyte suspensions were prepared and analyzed in the ex vivo reactivation assay or used for DNA isolation 
for real-time PCR analysis. (A) Spleen weights; (B) ex vivo reactivation of splenocytes; (C) viral genomic load 
in the spleen. Data shown in panel A are the means + standard deviations of 10 mice per group, compiled 
from three independent experiments. The asterisks indicate a statistically significant difference: *P = 0.021; 
**P = 0.009 (Student’s t-test). Data shown in panel B are the means ± standard errors of the means pooled 
from three independent experiments. In each experiment, splenocytes from two to five mice per group were 
pooled. The dashed line in panel B indicates the point of 63.2% Poisson distribution, determined by nonlinear 
regression, which was used to calculate the frequency of cells reactivating lytic replication. In panel C, each 
symbol represents an individual mouse, and the bars represent the median. The data are compiled from three 
independent experiments.
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load of latently infected cells in the spleen50,51. Thus, we first tested whether deletion of the MHV-68 sncRNAs 
has an effect on lytic replication in the lungs. For this purpose, IFN-γ-R−/− mice were inoculated i.n. with 5 × 104 
PFU of parental virus, sncRNA ko and sncRNA ko-revertant, respectively. Lungs of mice were harvested at 
day 3 (Fig. 7A) and at day 6 (Fig. 7B) after infection, and virus titers were determined from organ homogen-
ates by plaque assay. As in C57BL/6 mice, the sncRNA ko attained similar titers as parental virus and sncRNA 
ko-revertant (the latter displaying slightly higher titers), indicating that the sncRNAs are dispensable for lytic 
replication also in the lungs of IFN-γ-R−/− mice.
Early latency in IFN-γ-R−/− mice. Next, spleen weight, ex vivo reactivation of latently infected splenocytes 
and the viral genomic load in the spleen were determined 17 days after infection. To this end, IFN-γ-R−/− mice 
were inoculated i.n. with 5 × 104 PFU of parental virus, sncRNA ko and sncRNA ko-revertant, respectively. At 
day 17 after infection, spleens were harvested, and the spleen weights were taken. Single splenocyte suspensions 
were prepared and analyzed in the ex vivo reactivation assay or used for DNA isolation for real-time PCR anal-
ysis. After infection with the sncRNA ko, significantly higher spleen weights were observed, when compared to 
infection with parental virus or sncRNA ko-revertant (Fig. 8A). Ex vivo reactivation was approximately 10-fold 
reduced after infection with the sncRNA ko, with frequencies of reactivation being 1 in 2615, 1 in 20582 and 
1 in 1274 for parental virus, sncRNA ko and sncRNA ko-revertant, respectively (P = 0.057 for parental virus 
Figure 6. Late latency in the spleen of C57BL/6 mice. Mice were inoculated i.n. with 5 × 104 PFU of the 
indicated viruses. At day 42 after infection, spleens were harvested and used for DNA isolation for real-time 
PCR analysis to determine the viral genomic load. Each symbol represents an individual mouse, and the bars 
represent the median. The data are compiled from two independent experiments. The asterisks indicate a 
statistically significant difference: *P = 0.015; **P = 0.009 (Student’s t-test).
Figure 7. Lytic replication in the lungs of IFN-γ-R−/− mice. Mice were inoculated i.n. with 5 × 104 PFU of the 
indicated viruses. Lungs of mice were harvested at day 3 (A) and at day 6 (B) after infection. Virus titers were 
determined from organ homogenates by plaque assay. Each symbol represents an individual mouse, and the 
bars represent the median. The data are compiled from two to four independent experiments.
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versus sncRNA ko, and P = 0.133 for sncRNA ko versus sncRNA ko-revertant; Mann-Whitney Rank Sum Test) 
(Fig. 8B). In contrast, the viral genomic load in the spleen was not reduced after infection with the sncRNA ko 
(Fig. 8C). We conclude from these data that in IFN-γ-R−/− mice, the sncRNAs of MHV-68 contribute to the loss 
of splenocytes and to ex vivo reactivation but not to the overall genomic load in the spleen at early latency.
Late latency in IFN-γ-R−/− mice. Finally, we analyzed the viral genomic load at day 42 post infection. 
Notably, as in C57BL/6 mice, IFN-γ-R−/− mice infected with the sncRNA ko displayed a significantly higher viral 
genomic load when compared to infection with parental virus or sncRNA ko-revertant (P = 0.011 for parental 
virus versus sncRNA ko, and P = 0.002 for sncRNA ko versus sncRNA ko-revertant; Mann-Whitney Rank Sum 
Test) (Fig. 9). Again, as in C57BL/6 mice, the increase in viral genomic load was, however, not accompanied by 
an increased ex vivo reactivation. These data indicate that the absence of the sncRNAs results in a higher viral 
genomic load in the spleen during late latency.
Pathogenesis in Balb/c IFN-γ−/− mice. Infection of Balb/c IFN-γ−/− mice with wildtype MHV-68 results 
in acute lethal pneumonia52. Since other authors45,46 demonstrated that the MHV-68 sncRNAs are required for 
this lethal pneumonia, we also wanted to test our sncRNA ko in this system. For this purpose, Balb/c IFN-γ−/− 
mice were inoculated i.n. with 4 × 105 PFU of parental virus, sncRNA ko and sncRNA ko-revertant, respectively, 
or were left uninfected. Subsequently, mice were monitored daily for signs of disease and the body weight was 
determined. Any mice that appeared moribund or lost more than 15% of the initial body weight were sacrificed 
by cervical dislocation, and lungs were taken for further analyses. As shown in Fig. 10, no differences regarding 
Figure 8. Early latency in the spleen of IFN-γ-R−/− mice. Mice were inoculated i.n. with 5 × 104 PFU of the 
indicated viruses. At day 17 after infection, spleens were harvested, and the spleen weights were taken. Single 
splenocyte suspensions were prepared and analyzed in the ex vivo reactivation assay or used for DNA isolation 
for real-time PCR analysis. (A) Spleen weights; (B) ex vivo reactivation of splenocytes; (C) viral genomic load in 
the spleen. Data shown in panel A are the means + standard deviations of 13 (parental virus), 11 (sncRNA ko) 
and 5 (sncRNA ko-revertant) mice per group, compiled from two to four experiments. The asterisks indicate 
a statistically significant difference: *P = 0.007; **P = 0.046 (Student’s t-test). Data shown in panel B are the 
means ± standard errors of the means pooled from two to four independent experiments. In each experiment, 
splenocytes from two to five mice per group were pooled. The dashed line in panel B indicates the point of 
63.2% Poisson distribution, determined by nonlinear regression, which was used to calculate the frequency 
of cells reactivating lytic replication. In panel C, each symbol represents an individual mouse, and the bars 
represent the median. The data are compiled from two to four independent experiments.
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Figure 9. Late latency in the spleen of IFN-γ-R−/− mice. Mice were inoculated i.n. with 5 × 104 PFU of the 
indicated viruses. At day 42 after infection, spleens were harvested and used for DNA isolation for real-time 
PCR analysis to determine the viral genomic load. Each symbol represents an individual mouse, and the bars 
represent the median. The data are compiled from two to four independent experiments. The asterisks indicate a 
statistically significant difference: *P = 0.011; **P = 0.002 (Mann-Whitney Rank Sum test).
Figure 10. Pathogenesis in Balb/c IFN-γ−/− mice. Mice were inoculated i.n. with 4 × 105 PFU of the indicated 
viruses. Mice were monitored daily for signs of disease, and the body weight was determined at the indicated 
time points. Any mice that appeared moribund or lost more than 15% of the initial body weight (indicated by 
the dashed line) were sacrificed by cervical dislocation, and lungs were taken for further analyses. (A) weight 
loss; (B) survival; (C) virus titer in the lungs at day 6 after infection. Data shown in panels A (mean ± SD) and 
B are derived from 7 (uninfected), 11 (parental virus), 11 (sncRNA ko) and 11 (sncRNA ko-revertant) mice 
per group. The data are compiled from two independent experiments. In panel C, each symbol represents an 
individual mouse, and the bars represent the median.
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weight loss (Fig. 10A), survival (Fig. 10B) and viral lung titers at day 6 after infection (Fig. 10C) were observed 
between the mice infected with the different viruses.
Discussion
In MHV-68, the miRNAs are located downstream of the vtRNAs. For this reason, these very tightly linked ele-
ments are also called TMERs (tRNA-miRNA-encoding RNAs)45,46. A practical consequence is that it might be 
inherently difficult to separate potential functions of the vtRNAs and miRNAs from each other. A first attempt in 
this direction was recently undertaken by Diebel et al.46, suggesting an independent functional role of the vtRNAs 
in acute infection and pathogenesis. Yet, in general, uncovering the functions of the vtRNA-miRNA-encoding 
sequences is still in its beginning.
Consequently, at this stage, we decided to investigate the effect of a combined deletion of both vtRNAs and 
miRNAs using a mutant lacking both types of sncRNAs. The data obtained with our mutant are mostly con-
sistent with the previous findings of Feldman et al.45 and Diebel et al.46. Specifically, we also observed that the 
sncRNAs of MHV-68 are dispensable for lytic replication both vitro and in vivo. In contrast, at early latency in 
C57BL/6 wildtype mice, a mutant lacking the sncRNAs was slightly attenuated as reflected by reduced spleen 
weight, reduced B cell expansion and reduced ex vivo reactivation. Interestingly, this was not accompanied by a 
reduced overall viral genomic load. We also investigated our mutant in IFN-γ-R−/− mice, thereby extending the 
previous studies to an additional in vivo model. In IFN-γ-R−/− mice, we observed similar results as in C57BL/6 
wildtype mice, thus validating the findings.
Surprisingly, in Balb/c IFN-γ−/− mice, we obtained completely different results when compared to the pre-
vious studies. While Feldman et al.45 and Diebel et al.46 observed a striking attenuation of lethal pneumonia in 
Balb/c IFN-γ−/− mice after infection with their respective mutants, we did not observe a reduced virulence of our 
mutant in this model of viral pneumonia52. However, we think that this difference can most likely be explained by 
the fact that we, according to our national animal welfare rules, sacrificed the animals when they lost more than 
15% of the initial body weight. We assume that in the studies of Feldman et al.45 and Diebel et al.46, the mice got 
the opportunity to recover.
Most importantly, while we, like Feldman et al.45 and Diebel et al.46, also investigated acute lytic replication 
and early latency, we additionally analyzed late latency (around six weeks after infection). This appeared very 
interesting to us as it has been proposed that the use of ncRNAs might be of particular advantage for the virus 
during tight latency. At this stage, hardly any viral proteins are expressed to avoid recognition by the immune 
system, and thus, ncRNAs might be exploited since they are less likely to be recognized by the immune system2. In 
particular, it has been proposed that ncRNAs directly or indirectly contribute to the maintenance of latency, either 
by targeting pivotal viral lytic genes or by targeting cellular regulatory pathways used to control latency16,19,20,53,54. 
For gammaherpesviruses, this has been shown for KSHV where viral miRNAs help to maintain latency by medi-
ating the repression of RTA (replication and transcription activator) or by targeting the NF-kB pathway, and it 
has also been shown for EBV where viral miRNAs help to maintain latency by targeting BALF5 (the EBV DNA 
polymerase) or by targeting Dicer (see references 12, 18, 19, 53–55 for recent reviews). The studies with KSHV 
and EBV have all been performed in vitro. Therefore, until now, no information was available whether gamma-
herpesviral sncRNAs may also contribute to the maintenance of latency in vivo. We investigated this issue by 
analyzing the phase of late latency (around six weeks after infection) in the MHV-68 model.
In the absence of the sncRNAs, we observed a higher viral genomic load during late latency in the spleens of 
both C57BL/6 wildtype and IFN-γ-R−/− mice. We speculate that the increased viral genomic load during late 
latency is due to a disturbed regulation of the balance between latent and lytic infection. The increase in viral 
genomic load was not accompanied by an increased ex vivo reactivation. However, it is known that at six weeks 
post infection, only very few latently infected splenocytes reactivate in the ex vivo reactivation assay39. At the 
moment, we do neither understand the molecular mechanisms nor do we know whether the observed effects are 
related to the MHV-68 miRNAs, to the vtRNAs or to a combination of both. Clearly, much more work with more 
sophisticated mutants will be necessary to separate the potential functions of the vtRNAs and miRNAs from each 
other. In this regard, Feldman et al.56 very recently showed for the first time a miRNA-independent function of a 
MHV-68 TMER: TMER4 was shown to be important for hematogenous dissemination of MHV-68 and for the 
establishment of latency at peripheral sites. In addition, to understand the regulation exerted by the sncRNAs, in 
particular by the miRNAs, we need to know potential targets of the MHV-68 miRNAs. Until now, only a bioinfor-
matical prediction of putative targets has been performed but no targets have been validated so far57.
Taken together, we demonstrated that during late latency, the absence of the MHV-68 sncRNAs results in a 
higher viral genomic load in the spleen. Hence, we provide for the first time evidence that gammaherpesvirus 
sncRNAs contribute to the maintenance of latency in vivo.
Methods
Cell lines. BHK-21 cells (American Type Culture Collection [ATCC]: CCL-10) were grown in Glasgow-MEM 
(PAN Biotech, Aidenbach, Germany) supplemented with 5% fetal calf serum (FCS; PAN Biotech, Aidenbach, 
Germany), 5% Tryptose Phosphate Broth, 2 mM L-Glutamine, 100 U/ml Penicillin and 100 μg/ml Streptomycin. 
REF-Cre cells47 were maintained in DMEM High Glucose (Gibco, Darmstadt, Germany) with 10% FCS, 2 mM 
L-Glutamine, 100 U/ml Penicillin, 100 μg/ml Streptomycin and 500 μg/ml G418 (PAA, Pasching, Austria). 
NIH3T3 cells (ATCC: CRL-1658) were grown in DMEM High Glucose (Gibco, Darmstadt, Germany) in the 
presence of 10% FCS, 2 mM L-Glutamine, 100 U/ml Penicillin and 100 μg/ml Streptomycin.
Plasmid construction and analysis of BAC plasmids. Using MHV-68 cloned as bacterial artificial chro-
mosome (BAC) (designated as parental virus)47, we constructed a mutant lacking all known sncRNAs (named as 
sncRNA ko) and a revertant of this mutant (called as sncRNA ko - revertant) as follows:
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(1) The mutant virus sncRNA was created by three consecutive rounds of markerless BAC mutagenesis as 
described previously58. First, nucleotides 196 to 1788 were deleted (thereby deleting tRNAs 1–5 including 
miRNAs 1–7 and 10–12) using the forward primer 5′-TAG AGC AAC AGG TCA CCG ATC CTG GTG GTT 
CTC GGT TCA AGT CCG AGC TCA GGA TGA CGA CGA TAA GTA GGG-3′ and the reverse primer 
5′-TGT TCT TGT TTT GGT GGG AGG CTA GAT GGT CGT GGG CGG CCT GTG GAG CAG AGC TCG 
GAC TTG AAC CGA GAA CCA CCA GGA TCG GTG ACC TGT TGC TCT ACA ACC AAT TAA CCA 
ATT CTG ATT AG-3′. Second, nucleotides 3749 to 3876 were deleted (thereby deleting miRNAs 8 and 13 
and possibly also affecting tRNA 6) using the forward primer 5′-GCA GCG GCC ACC AAG CCT GCA GGT 
TCT CGG TTC AAG TCC GGG CGC TGG CAA GGA TGA CGA CGA TAA GTA GGG-3′ and the reverse 
primer 5′-ACA CTC TTT TAC AAC CCT AGG AGA GCC AGA TAA AAA TTT TGT GTT AAG CAT GCC 
AGC GCC CGG ACT TGA ACC GAG AAC CTG CAG GCT TGG TGG CCG CTG CCA ACC AAT TAA 
CCA ATT CTG ATT AG-3′. Finally, nucleotides 5102 to 5584 were deleted (thereby deleting miRNA14 and 
tRNA 8 including miRNAs 9 and 15, and possibly also affecting tRNA7) using the forward primer 5′-CAA 
ACT GTG TGG TGG GAC TCT GCA GAC TTG GCA GTT CTG CAG CAG TCA GCA GGA TGA CGA 
CGA TAA GTA GGG-3′ and the reverse primer 5′-GTG TCC TAA ATT CTG AGG CCA ATG GAA AGG 
TGA GCA TGT CTT GGG TGG CAG CTG ACT GCT GCA GAA CTG CCA AGT CTG CAG AGT CCC 
ACC ACA CAG TTT GCA ACC AAT TAA CCA ATT CTG ATT AG-3′.
(2) To exclude the possibility that the observed results were due to rearrangements outside the mutated regions, 
a revertant of the sncRNAs ko mutant (sncRNA ko - revertant) was generated by the two-step mutagenesis 
procedure47,59. For that purpose, a 1783 bp HindIII - StuI fragment of MHV-68 (nucleotide positions 106 
to 1889) was cloned blunt end into the BglII site (nucleotide position 3846 of the MHV-68 genome) of the 
plasmid pST76K-SR M1/M260. As a result, the 1783 bp fragment is flanked on both sides by homologous 
sequences (position 2406–3846 as 5′ flank and position 3847–6261 as 3′ flank) as needed for homologous 
recombination during the two-step mutagenesis procedure.
All BAC plasmids were characterized by restriction enzyme and Southern blot analysis and by sequencing 
across the mutated regions.
Reconstitution of recombinant MHV-68. To reconstitute recombinant MHV-68, BHK-21 cells were 
transfected with 2 μg of the appropriate BAC MHV-68 DNA using X-treme GENE HP DNA Transfection Reagent 
(Roche, Mannheim, Germany). When cells showed a total cytopathic effect (CPE), an aliquot of the supernatant 
was used to infect REF-Cre cells carrying the Cre recombinase to remove the BAC-cassette including the GFP 
sequence. BAC-cassette free viruses were identified by a limiting dilution assay on BHK-21 cells performed in a 
96 well plate. All recombinant viruses were grown and titrated on BHK-21 cells as previously described47.
Determination of viral gene expression by RT-PCR. NIH3T3 cells were cultured in 6-well plates and 
infected with the indicated viruses at an MOI of 1. For each virus, three biological replicates were done. Total RNA 
was isolated 48 hr p.i. using the RNeasy MiniKit (Qiagen, Hilden, Germany). Genomic DNA was removed with 
the TURBO DNA-free Kit (Ambion/Life Technologies, Darmstadt, Germany), and RNA was reverse-transcribed 
using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) or subjected to 
mock reverse transcription in the absence of the enzyme (-RT control). The expression of the MHV-68 genes 
M1, M2 and M3 and of the cellular ribosomal Protein L8 gene was analyzed by real time quantitative PCR using 
Taqman SYBR green PCR master mix (Applied Biosystems, Foster City, CA) and the ABI 7300 Real Time PCR 
System (Applied Biosystems, Foster City, CA). The following PCR primer sets were used: L8: forward 5′-CAG 
TGA ATA TCG GCA ATG TTT TG-3′; reverse 5′-TTC ACT CGA GTC TTC TTG GTC TC-3′. M1: forward 
5′-ATC TCA CCT TTG CTG GAT TCT TAT TTG C-3′; reverse 5′-GTT CTG ATG GCT TGA AAC GAT GGC-3′. 
M2: forward 5′-TCC TCG CCC CAC TCC ACA AAA C-3′; reverse 5′-AAC ACC CCA TGA ACC CTG AGA 
TAC G-3′. M3: forward 5′-GCT TGC TGG ATG GTC TCA CAG G-3′; reverse 5′-TAA GAT GAA CAC TTG 
CCC ATG CTA CTA C-3′.
Determination of miRNA expression by the recombinant MHV-68. NIH3T3 cells were cultured in 
6-well plates and infected with the indicated viruses at an MOI of 1, or were left uninfected. For each condition, 
three biological replicates were done. Total RNA was isolated 48 hr p.i. using the RNAeasy Mini-Kit (Qiagen, 
Hilden, Germany) according to the instructions of the manufacturer. RNA samples were then submitted to LC 
Sciences (Houston, Texas, USA). The expression analysis of the MHV-68 miRNAs was performed by LC Sciences 
using custom miRNA microarrays.
For samples derived from latently infected mice, quantification of miRNAs was performed as previously 
described by stemloop quantitative RT-PCR (qRT-PCR)41.
Analysis of in vitro growth properties of the recombinant MHV-68. To test in vitro growth of the 
virus mutants, NIH3T3 cells were infected with an MOI of 0.1 for 1 hour. After removing the inoculum, cells were 
incubated with fresh medium at 37 °C and 5% CO2 until the supernatants together with the cells were harvested 
at different time points after infection. Virus titers were determined by plaque assay.
In vivo experiments. C57BL/6 mice were purchased from Charles River Laboratories (Sulzfeld, Germany). 
IFN-γ-R−/− mice (on C57BL/6 background) and IFN-γ−/− mice (on Balb/c background) were originally 
obtained from the Jackson Laboratory (Bar Harbor, Maine, USA) and subsequently bred and propagated 
under SPF conditions at the Helmholtz Zentrum München. Mice were housed in individually ventilated cages 
(IVC) during the MHV-68 infection period. To characterize the recombinant MHV-68 in vivo, mice were 
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infected i.n. with 5 × 104 PFU. Prior to i.n. infection, mice were anesthetized with ketamine-xylazine or with 
medetomidine-midazolam-fentanyl. To determine virus titers, organs were harvested at the indicated time 
points after infection and homogenized by using the FASTPREP®-24 instrument (MP Biomedicals, Heidelberg, 
Germany). After two times freezing and thawing the homogenates, plaque assays were performed with 10-fold 
dilutions of the supernatants on BHK-21 cells. For the measurement of spleen weight, frequency of virus reac-
tivation and genomic load as well as for FACS analysis, spleens were harvested at the indicated time points after 
infection. For the determination of MHV-68 specific antibodies, blood was collected at the indicated time points 
after infection. Mice were monitored daily for signs of disease, and any mice that appeared moribund were sacri-
ficed by exposure to CO2 or by cervical dislocation.
Ethics Statement. All animal experiments were in compliance with the German Animal Welfare Act 
(German Federal Law §8 Abs. 1 TierSchG), and the protocols were approved by the local Animal Care and Use 
Committee (District Government of Upper Bavaria; permit number 124-08 and 154-13).
Limiting dilution reactivation assay. To determine the frequency of cells carrying virus reactivating from 
latency, threefold dilutions of splenocytes were plated onto NIH 3T3 cells as described previously61. Frequencies 
of reactivating cells were calculated on the basis of the Poisson distribution by determining the cell number at 
which 63.2% of the wells scored positive for CPE.
Measurement of latent viral load by real time PCR. Viral load in the spleens of infected mice was 
determined by quantitative real-time PCR using the ABI 7300 Real Time PCR System (Applied Biosystems, 
Foster City, CA) as described previously62.
Determination of MHV-68 specific antibodies. To quantify MHV-68 specific antibodies in sera of 
mice, an ELISA was performed as described by Ruiss et al.63. Briefly, Nunc Maxisorp plates (Nunc, Wiesbaden, 
Germany) were coated with 3 μg/ml of MHV-68 lysate (prepared by disrupting MHV-68 via dilution in 
PBS/0.05% Triton X-100) for 90 min at 37 °C and stored overnight (4 °C). After washing with PBS/Tween, plates 
were blocked with PBS/Tween containing 5% FCS for 1 hour and washed again. Diluted sera (1:50) including pos-
itive and negative control sera were incubated for 1 h. For each sample, triplicates were performed. After washing, 
bound antibody was detected with HRP-conjugated rat anti-mouse antibody (Promega, Mannheim, Germany) 
and TMB (Becton Dickinson, Heidelberg, Germany) as substrate. Reactions were stopped with 1 M phosphoric 
acid and absorbance was read at 450 nm (Tecan Sunrise, Switzerland).
FACS analysis. The following fluorescent dye-conjugated anti-mouse monoclonal antibodies (mAbs) were 
used to evaluate and quantify amounts and phenotypes of splenocytes after infection by FACS: CD3-FITC (clone: 
17A2), CD4-PE (RM4-5), CD8a-PE (53-6.7), CD19-PE (PeCa1) and NK1.1-PE (PK136). mAbs were purchased 
from either BD/Pharmingen (Heidelberg, Germany) or ImmunoTools (Friesoythe, Germany). Cells were incu-
bated with mAbs (PBS + 2% FCS) according to manufacturer’s instructions, including appropriate isotype con-
trols. Data were evaluated on a FACS-Calibur-Flow-Cytometer using Cell-Quest-data acquisition and analysis 
software (BD).
Statistical methods. Datasets were tested for Gaussian distribution before statistical analysis by 
Shapiro-Wilk Normality Test using the SigmaPlot 12 software (Systat Software GmbH, Erkrath, Germany). 
When passing the normality test, data were analyzed by Student’s t-test. All other datasets were analyzed by 
Mann-Whitney Rank Sum Test. Results with a p-value < 0.05 were considered significant.
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